These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 29514612)
1. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. Margiotta DPE; Basta F; Batani V; Afeltra A BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612 [TBL] [Abstract][Full Text] [Related]
2. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM; Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482 [TBL] [Abstract][Full Text] [Related]
5. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558 [TBL] [Abstract][Full Text] [Related]
6. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial. Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800 [TBL] [Abstract][Full Text] [Related]
7. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Jesus D; Rodrigues M; da Silva JAP; Inês L Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lanata CM; Mahmood T; Fine DM; Petri M Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722 [TBL] [Abstract][Full Text] [Related]
9. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience. Mendonca S; Gupta D; Ali S; Gupta P Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065 [TBL] [Abstract][Full Text] [Related]
11. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045 [TBL] [Abstract][Full Text] [Related]
12. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Staveri C; Karokis D; Liossis SC Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Choi CB; Won S; Bae SC Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881 [TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103 [TBL] [Abstract][Full Text] [Related]
15. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis. Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325 [TBL] [Abstract][Full Text] [Related]
16. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis. Dimelow R; Liefaard L; Green Y; Tomlinson R Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441 [TBL] [Abstract][Full Text] [Related]
17. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil]. Suszek D; Wielosz E; Majdan M Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy. Nawata T; Kubo M; Fujii S; Shiragami K; Ikegami T; Kobayashi S; Hisano S; Yano M Intern Med; 2018 Jul; 57(14):2067-2070. PubMed ID: 29491296 [TBL] [Abstract][Full Text] [Related]
19. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis. Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]